已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Factors Associated With Short-term Relapse in Patients With Pemphigus Who Receive Rituximab as First-line Therapy

医学 美罗华 天疱疮 内科学 强的松 养生 随机对照试验 皮肤病科 淋巴瘤
作者
Claire Mignard,Maud Maho‐Vaillant,Marie-Laure Golinski,Pierre Balayé,Catherine Prost‐Squarcioni,Estelle Houivet,Sébastien Calbo,Bruno Labeille,Catherine Picard‐Dahan,Maria Polina Konstantinou,G. Chaby,M. Aleth Richard,Jean‐David Bouaziz,Sophie Duvert‐Lehembre,Emmanuel Delaporte,Philippe Bernard,Frédéric A. Caux,Marina Alexandre,S. Oro,Pierre Vabres
出处
期刊:JAMA Dermatology [American Medical Association]
卷期号:156 (5): 545-545 被引量:71
标识
DOI:10.1001/jamadermatol.2020.0290
摘要

Importance: Rituximab and short-term corticosteroid therapy are the criterion standard treatments for patients with newly diagnosed moderate to severe pemphigus. Objective: To examine factors associated with short-term relapse in patients with pemphigus treated with rituximab. Design, Setting, and Participants: This post hoc analysis of a randomized clinical trial (Comparison Between Rituximab Treatment and Oral Corticosteroid Treatment in Patients With Pemphigus [RITUX 3]) conducted from January 1, 2010, to December 31, 2015, included patients from 20 dermatology departments of tertiary care centers in France from the RITUX 3 trial and 3 newly diagnosed patients treated according to the trial protocol. Data analysis was performed from February 1 to June 30, 2019. Exposure: Patients randomly assigned to the rituximab group in the RITUX 3 trial and the 3 additional patients were treated with 1000 mg of intravenous rituximab on days 0 and 14 and 500 mg at months 12 and 18 combined with a short-term prednisone regimen. Main Outcomes and Measures: Baseline (pretreatment) clinical and biological characteristics (Pemphigus Disease Area Index [PDAI] score, ranging from 0-250 points, with higher values indicating more severe disease) and changes in anti-desmoglein (DSG) 1 and anti-DSG3 values as measured by enzyme-linked immunosorbent assay during the 3 months after rituximab treatment were compared between patients with disease relapse and those who maintained clinical remission during the first 12 months after treatment. The positive and negative predictive values of these factors were calculated. Results: Among 47 patients (mean [SD] age, 54.3 [17.0] years; 17 [36%] male and 30 [64%] female) included in the study, the mean (SD) baseline PDAI score for patients with relapsing disease was higher than that of the patients with nonrelapsing disease (54 [33] vs 28 [24]; P = .03). At month 3, 7 of 11 patients with relapsing disease (64%) vs 7 of 36 patients with nonrelapsing disease (19%) had persistent anti-DSG1 antibody values of 20 IU/mL or higher and/or anti-DSG3 antibody values of 130 IU/mL or higher (P = .01). A PDAI score of 45 or higher defining severe pemphigus and/or persistent anti-DSG1 antibody values of 20 IU/mL or higher and/or anti-DSG3 antibody values of 130 IU/mL or higher at month 3 provided a positive predictive value of 50% (95% CI, 27%-73%) and a negative predictive value of 94% (95% CI, 73%-100%) for the occurrence of relapse after rituximab. Conclusions and Relevance: The findings suggest that initial PDAI score and changes in anti-DSG antibody values after the initial cycle of rituximab might help differentiate a subgroup of patients with high risk of relapse who might benefit from maintenance rituximab infusion at month 6 from a subgroup of patients with low risk of relapse who do not need early maintenance therapy. Trial Registration: NCT00784589.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
风吹麦浪发布了新的文献求助10
刚刚
江就发布了新的文献求助10
1秒前
芝士小歪发布了新的文献求助10
1秒前
2秒前
乐乐的应助被Apple采纳,获得10
3秒前
猪四郎完成签到 ,获得积分10
5秒前
hjzno_1完成签到 ,获得积分10
7秒前
pik完成签到,获得积分20
9秒前
五岳三鸟完成签到,获得积分10
9秒前
摇摇晃晃完成签到 ,获得积分10
10秒前
10秒前
10秒前
11秒前
12秒前
SciGPT的应助被手提袋子的猫采纳,获得10
12秒前
13秒前
长情的寇完成签到 ,获得积分10
13秒前
77完成签到,获得积分10
13秒前
13秒前
14秒前
木华发布了新的文献求助10
15秒前
15秒前
胡图图完成签到 ,获得积分20
15秒前
酷波er的应助被无情妙菡采纳,获得10
16秒前
16秒前
科研通AI6.3的应助被积极北上采纳,获得10
16秒前
时老完成签到 ,获得积分10
17秒前
17秒前
Parker发布了新的文献求助10
19秒前
19秒前
hmv发布了新的文献求助10
20秒前
Arvin发布了新的文献求助10
20秒前
ar发布了新的文献求助10
21秒前
魏魏完成签到,获得积分10
21秒前
21秒前
zhzhzh发布了新的文献求助10
22秒前
Owen的应助被杨家南采纳,获得10
23秒前
23秒前
不吃鸭梨完成签到,获得积分10
25秒前
砍柴少年发布了新的文献求助10
25秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
Grapes 1000
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8179104
求助须知:如何正确求助?哪些是违规求助? 9569680
关于积分的说明 21806134
捐赠科研通 7774263
什么是DOI,文献DOI怎么找? 3433003
关于科研通互助平台的介绍 2556897
邀请新用户注册赠送积分活动 2478643